Display Settings:

Format

Send to:

Choose Destination
    Orthop Clin North Am. 2006 Jan;37(1):15-22.

    Advances in chemotherapy for patients with extremity soft tissue sarcoma.

    Source

    University of California, Los Angeles, UCLA Medical Center, 90095-1782, USA. fceilber@mednet.ucla.edu

    Abstract

    Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does. This benefit is likely histology- and size-specific. Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas.

    PMID:
    16311108
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk